TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Documenti analoghi

• Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
  di: Jørgensen, Charlotte LT, et al.
  Pubblicazione: (2013)
• Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
  di: Munro, Alison F, et al.
  Pubblicazione: (2013)
• Danish Breast Cancer Cooperative Group
  di: Christiansen, Peer, et al.
  Pubblicazione: (2016)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  di: Iben Kümler, et al.
  Pubblicazione: (2019-06-01)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  di: Kümler, Iben, et al.
  Pubblicazione: (2019)